{
  "abstract": "The D-dimer is a stable termination product of fibrin degradation. It was introduced as a biomarker of coagulation activation in the early 1970s and first evaluated as a test to exclude venous thromboembolism (VTE) in the 1980s.1 It has since been widely adopted into diagnostic care pathways across the world, despite well-documented issues with variation across laboratory assays and reporting units.2 D-dimer is often viewed as a dichotomous test (positive or negative) based on the standard threshold of 500 ng/mL fibrinogen equivalent units (FEUs) used in original derivation studies, despite being a continuous variable.3 Like so many tests in medicine, there is potential for more effective use.",
  "authors": [
    {
      "affiliations": [
        "Emergency Department, Northern Care Alliance NHS Foundation Trust, Salford, UK",
        "Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Manchester, UK"
      ],
      "name": "Daniel Horner"
    },
    {
      "affiliations": [
        "King’s Thrombosis Centre, Department of Haematological Medicine, King’s College Hospital NHS Foundation Trust, London, UK",
        "King’s College London, London, England, UK"
      ],
      "name": "Lara N Roberts"
    }
  ],
  "title": "Pulmonary embolism diagnosis and the D-dilemma",
  "uid": "f1e53207-5bca-549b-a9ba-c548e2a9969a"
}